The Ebos Group's first half result exceeded Morgans expectations as revenue grew by 6.3% to $4.7bn and underlying earnings (EBITDA) were up 9.3% to $184.1m. All divisions improved except for consumer products.

Two acquisitions were made during the period totaling $23m and management noted the acquisition pipeline remains active with a focus on medical devices.

The analyst increases forecast profit (NPAT) for FY21-23 by 3.2%, 6.1% and 9.2%, respectively, and lifts the target to $28.90 from $25.94. The Add rating is maintained.

Sector: Health Care Equipment & Services.

Target price is $28.90.Current Price is $27.24. Difference: $1.66 - (brackets indicate current price is over target). If EBO meets the Morgans target it will return approximately 6% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2021 Acquisdata Pty Ltd., source FN Arena